Steven Holtzman joins Satori's board
This article was originally published in Scrip
Executive Summary
Steven Holtzman, CEO and co-founder of Infinity Pharmaceuticals, has joined the board of directors at Satori Pharmaceuticals (US), a privately held developer of therapeutics for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.